Recombinant Uncharacterized HTH-type transcriptional regulator Rv1985c/MT2039 (Rv1985c, MT2039)

What is Rv1985c and what are its basic structural properties?

Rv1985c is an HTH-type (helix-turn-helix) transcriptional regulator encoded in the genome of Mycobacterium tuberculosis. The protein consists of 303 amino acids with a coding sequence (CDS) located at positions 2228991-2229902 on the negative strand, spanning 912 nucleotides. Its molecular weight is approximately 33.886 kDa based on theoretical mass prediction, which has been confirmed by experimental validation showing a measured weight of 33.892 kDa through HPLC analysis . Structurally, Rv1985c contains DNA-binding domains characteristic of transcriptional regulators and has been alternatively annotated as a "chromosome replication initiation inhibitor protein" in some database references .

Where is Rv1985c located within the Mycobacterium tuberculosis genome?

Rv1985c is located within Region of Difference 2 (RD2) of the Mycobacterium tuberculosis genome. This positioning is significant because RD regions constitute a potential source of specific antigens for immunodiagnosis, as these genomic segments are present in M. tuberculosis but absent in BCG vaccine strains. The gene is positioned on the negative strand at coordinates 2228991-2229902 and is part of operon #1297 .

Is Rv1985c expressed in Mycobacterium tuberculosis cultures?

Yes, Rv1985c expression at the mRNA level has been verified through RT-PCR studies. These experiments revealed an expected 930-bp PCR product during gel electrophoresis, confirming that Rv1985c is expressed during in vitro growth. No PCR product was detected in the absence of reverse transcriptase, validating the specificity of the detected expression .

What are the recommended protocols for recombinant expression of Rv1985c?

The recombinant expression of Rv1985c typically involves cloning the coding sequence into an expression vector containing a C-terminal 6-Histidine tag. After transformation into an appropriate E. coli expression system, the protein is largely found in the soluble fraction (supernatant) following cell lysis, which facilitates purification. Expression verification can be performed using monoclonal anti-His tag antibodies. The reported yield is approximately 4.1 mg of purified protein per liter of bacterial culture .

How can researchers purify Rv1985c to high levels of purity for experimental use?

Purification of Rv1985c can be achieved using nickel affinity chromatography targeting the C-terminal 6-Histidine tag. Following initial capture, further purification steps may include size exclusion chromatography. Quality control should include SDS-PAGE analysis, where a single 34-kDa protein band should be observed, and HPLC analysis to confirm purity levels. Published protocols have achieved purity levels of 98.7% for recombinant Rv1985c, making the protein suitable for immunological assays and structural studies .

What gene modules is Rv1985c co-regulated with in Mycobacterium tuberculosis?

Rv1985c is predicted to be co-regulated in two specific modules: bicluster_0007 with a residual value of 0.55 and bicluster_0380 with a residual value of 0.52. This co-regulation is potentially mediated by de-novo identified cis-regulatory motifs, with e-values of 0.00 for both motifs in bicluster_0007 and e-values of 0.07 and 0.10 for the two motifs in bicluster_0380. These patterns suggest Rv1985c participates in coordinated gene expression networks within the pathogen .

What is the connection between Rv1985c and cholesterol metabolism in M. tuberculosis?

Research data indicates that Rv1985c is involved in growth on cholesterol, although the specific mechanistic details remain to be fully elucidated. This connection to cholesterol metabolism is significant because cholesterol utilization is critical for M. tuberculosis persistence during infection, particularly in the chronic phase. Understanding Rv1985c's role in this process could provide insights into bacterial adaptation mechanisms within host environments .

How effective is Rv1985c as a diagnostic antigen for tuberculosis infection?

Rv1985c shows considerable promise as a diagnostic antigen for tuberculosis. In T-cell assays, IFN-γ Rv1985c-ELISPOT achieves 71% sensitivity in detecting active TB and 55% sensitivity in detecting latent TB infection (LTBI). For humoral response detection, Rv1985c IgG-ELISA reaches 52% and 62% sensitivity in detecting active TB, outperforming commercial kits like PATHOZYME-MYCO (34% sensitivity, P = 0.011). Most importantly, when combined with other antigens like ESAT-6 and CFP-10, Rv1985c significantly improves detection sensitivity, particularly increasing CFP-10's sensitivity from 67.9% to 87.5% (P < 0.001) .

How does Rv1985c induce immune responses in TB and LTBI patients compared to healthy controls?

Rv1985c induces significantly stronger T-cell responses in both TB and LTBI groups compared to healthy controls (P < 0.001), as measured by Spot Forming Units (SFU) in IFN-γ ELISPOT assays. ROC curve analysis for Rv1985c shows an area under the curve of 0.836 (95% CI, 0.746-0.927), indicating good diagnostic potential. Using an optimal cut-off level of 4.5 SFU, 71% of TB patients and 55% of LTBI individuals test positive, while only 3% of healthy controls show positive results. This differential immune recognition makes Rv1985c particularly valuable for distinguishing infected individuals from BCG-vaccinated controls .

What are the recommended protocols for developing Rv1985c-based immunoassays?

For cellular response detection, IFN-γ ELISPOT assays can be developed using purified recombinant Rv1985c as the stimulating antigen with peripheral blood mononuclear cells (PBMCs). The recommended cut-off value is 4.5 SFU based on ROC curve analysis to optimize sensitivity and specificity. For humoral response detection, IgG-ELISA assays using recombinant Rv1985c as the capture antigen are recommended. In both assay types, positive and negative controls should be included, and results should be compared with commercial kits (like T-SPOT.TB or PATHOZYME-MYCO) for validation. Combined assays incorporating Rv1985c with ESAT-6 and CFP-10 are particularly advantageous for improving diagnostic sensitivity .

How can differential expression data for Rv1985c inform experimental design?

The differential expression data for Rv1985c provides valuable information for designing experiments that investigate its regulatory functions. The data shows varied expression levels under different conditions, with some conditions showing significant induction (p-values as low as 0.000000221) and others showing repression (p-values as low as 0.000000000319). Experiments should be designed to incorporate these conditions to effectively study Rv1985c's regulatory mechanisms. The table below summarizes key differential expression data:

This data suggests strategic time points and conditions for sampling to capture maximum regulatory activity .

What contradictions exist in the annotated functions of Rv1985c and how should researchers interpret them?

There are notable contradictions in the functional annotations of Rv1985c across different databases. While it's primarily characterized as an "HTH-type transcriptional regulator" in most sources, RefSeq alternatively annotates it as a "chromosome replication initiation inhibitor protein." This dual annotation suggests potential multifunctionality, possibly acting both as a transcriptional regulator and having roles in replication control. Researchers should design experiments that test both hypothesized functions, perhaps examining DNA binding specificity through ChIP-seq while also investigating effects on replication timing when Rv1985c is overexpressed or deleted .

What bioinformatic approaches can be used to predict potential binding sites for Rv1985c?

To predict potential binding sites for Rv1985c, researchers can employ several bioinformatic approaches. First, the identified cis-regulatory motifs associated with bicluster_0007 (e-values 0.00) and bicluster_0380 (e-values 0.07 and 0.10) can serve as starting points for position weight matrix (PWM) construction. These PWMs can then be used to scan the M. tuberculosis genome for potential binding sites. Researchers should also perform comparative genomics analyses across mycobacterial species to identify evolutionarily conserved binding sites. ChIP-seq data integration, where available, can further refine predictions. Finally, structural modeling of the HTH domain can provide insights into DNA sequence preferences and binding specificities .

What factors might affect the solubility of recombinant Rv1985c and how can they be addressed?

While recombinant Rv1985c is reported to be largely present in the soluble fraction, researchers might encounter solubility issues under certain expression conditions. Factors that can affect solubility include expression temperature, induction concentration, and host strain selection. To address potential insolubility:

• Lower the expression temperature to 16-25°C to slow protein folding

• Reduce inducer concentration to decrease expression rate

• Consider fusion tags beyond His-tag, such as MBP or SUMO tags

• Test different E. coli expression strains, particularly those enhanced for difficult protein expression

• Optimize buffer conditions during purification, testing various pH values and salt concentrations

• Include stabilizing agents such as glycerol or specific detergents if hydrophobic regions are causing aggregation

How can researchers address potential cross-reactivity issues when using Rv1985c for TB diagnosis?

When developing Rv1985c-based diagnostic assays, researchers should implement several strategies to address potential cross-reactivity:

• Include comprehensive control panels featuring samples from individuals with non-TB mycobacterial infections

• Perform epitope mapping to identify Rv1985c regions unique to M. tuberculosis

• Use bioinformatic analysis to predict potential cross-reactive epitopes with other mycobacterial species

• Consider combination assays with other TB-specific antigens (ESAT-6, CFP-10) to increase specificity

• Implement more stringent cut-off values if cross-reactivity is observed

• Develop blocking steps using recombinant proteins from cross-reactive species

• Perform pre-absorption of sera with lysates from non-tuberculous mycobacteria when testing antibody responses

What are promising research areas for further characterizing Rv1985c's role in M. tuberculosis pathogenesis?

Several promising research directions could further elucidate Rv1985c's role in pathogenesis:

• Generating knockout and complemented strains to assess virulence in animal models

• Performing ChIP-seq to identify the complete Rv1985c regulon across different infection stages

• Investigating the connection between Rv1985c and cholesterol metabolism through metabolomic approaches

• Examining Rv1985c expression during different stages of infection and in response to host immune factors

• Exploring potential protein-protein interactions that might modulate Rv1985c activity

• Determining the three-dimensional structure of Rv1985c to enable structure-based functional studies

• Investigating the dual functionality as both a transcriptional regulator and potential chromosome replication inhibitor

How might Rv1985c interact with host immune response pathways during infection?

Research into Rv1985c's interactions with host immune response pathways could explore:

• Characterization of specific T-cell epitopes within Rv1985c that elicit strong immune responses

• Investigation of Rv1985c's potential interference with host signaling pathways following cellular internalization

• Analysis of how Rv1985c expression changes in response to host immune pressures

• Examination of potential post-translational modifications of Rv1985c during infection that might alter immunogenicity

• Exploration of Rv1985c's role in modulating cytokine production in infected cells

• Assessment of whether Rv1985c affects antigen presentation pathways in infected macrophages

• Investigation of potential differences in immune response to Rv1985c between active TB and LTBI individuals